MMSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the data provided, Merit Medical Systems Inc (MMSI) does not present a compelling buy opportunity for a beginner investor with a long-term strategy at this time. The technical indicators are bearish, the options data shows neutral sentiment, and recent analyst downgrades highlight uncertainty in growth and guidance. While the company's financial performance in Q4 2025 was strong, the lack of clear catalysts and the recent downgrade by Wells Fargo suggest a cautious approach. Holding the stock or waiting for a better entry point may be more prudent.
The technical indicators for MMSI are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 29.842, and the moving averages show a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 77.776, with resistance at 80.588 and 83.399.
Strong Q4 2025 financial performance with 11% YoY revenue growth and 36% YoY EPS growth.
Record free cash flow of $74 million.
Positive long-term outlook from some analysts, such as BTIG and Barrington, citing healthy end markets and potential for multiple expansion.
Recent downgrade by Wells Fargo to Equal Weight from Overweight, citing uncertainty in fiscal 2026 guidance and lack of growth catalysts.
Bearish technical indicators and pre-market price trading near support levels.
Neutral sentiment from hedge funds and insiders, with no significant trading trends.
In Q4 2025, Merit Medical reported revenue of $393.9 million, up 10.92% YoY, net income of $38 million, up 35.99% YoY, and EPS of $0.63, up 36.96% YoY. Gross margin increased to 49.59%, up 1.81% YoY, indicating strong operational performance.
Analyst sentiment is mixed. Recent downgrades by Wells Fargo (to Equal Weight with a price target of $78) and Baird (lowered price target to $104) highlight concerns about guidance uncertainty. However, firms like Barrington and BTIG maintain positive outlooks with price targets of $109 and $107, respectively, citing strong financials and healthy end markets.
